An Iranian study of 504 men showed daily supplementation with an EPAX omega 3 triglyceride (TG) concentrate may help reduce PSA levels, a marker for prostate cancer risk. The study titled “Effects of EPA, y-linolenic acid or coenzyme Q10 on serum prostate-specific antigen levels: a randomized, double-blind trial,” published in the British Journal of Nutrition
, showed how omega 3 fatty acids and coenzyme Q10 can alter serum prostate-specific antigen (PSA) levels in healthy men. Participants were randomly assigned to receive supplementation of one of three products: Epax 5500 TG omega 3, Nutri Q10, 2,400mg of GLA , or a placebo for 12 weeks. Use of the EPAX TG concentrate resulted in a 30% reduction in PSA levels, with a 33% drop with Nutri Q10. Supplements containing omega 6 (GLA) were linked to an increase in PSA levels. EPAX 5500 TG is a marine-derived omega 3 of 280mg/g EPA and 180mg/g DHA fatty acids and is a previous version of EPAX 6000 TG.
For further information: http://journals.cambridge.org